Mold isn’t just a stain on your basement wall. It’s the silent tenant squatting in half of U.S. homes and 85% of commercial buildings, triggering illnesses that look like everything and get treated like nothing. Doctors shrug, patients bounce from one misdiagnosis to another, and the cycle keeps spinning. Until one patient refused to stay in the spin. Ariana Thacker, once a venture investor, developed Chronic Inflammatory Response Syndrome after mold exposure and discovered firsthand that the system was cracked. She didn’t wait for permission. She built MoldCo.
MoldCo is a Boston-based telehealth platform designed to make mold detoxification as routine as a cholesterol check. The service delivers standardized screenings, advanced biomarker lab tests starting at ninety-nine dollars, and prescription-strength therapies shipped to your door. Behind the protocols sits nearly three decades of peer-reviewed research from Dr. Ritchie Shoemaker, the physician who pioneered the field of biotoxin illness. His work has touched more than thirty thousand patients, but through MoldCo, it’s being scaled into a national standard of care.
That mission just secured serious backing. MoldCo closed an eight million dollar seed round led by Cantos and Collaborative Fund, joined by Starship Ventures, SALT, Conscience VC, Boost VC, Night Ventures, Bleu Capital, Behind Genius Ventures, and Moth Fund. Combined with a three million dollar pre-seed from December 2024, MoldCo now stands on eleven million raised. Congratulations to Founder and CEO Ariana Thacker and Founding Physician and Clinical Advisor Dr. Ritchie Shoemaker for aligning a coalition of believers who see where this market is headed.
The blueprint is aggressive. Expand virtual clinical coverage from five states to all fifty by 2026. Launch a mobile app that lets patients self-assess and track progress. Grow research collaborations to validate protocols and integrate environmental remediation partners into the ecosystem. It’s a platform built for scale, secured by HIPAA-compliant infrastructure, API-driven lab integrations, and e-prescribing systems designed to automate care delivery.
The numbers don’t lie. Preventive health is a one-hundred-billion-dollar market, and environmental health is the piece nobody is addressing at scale. MoldCo compresses treatment costs to one-fifth of what fragmented care demands, turning what was once a financial nightmare into a manageable monthly investment. This isn’t an incremental step. It’s a market correction waiting to happen.
